首页>Cancer chemotherapy and pharmacology.>Comparative assessment of pharmacokinetics, and pharmacodynamics between RTXM83?, a rituximab biosimilar, and rituximab in diffuse large B-cell lymphoma patients: a population PK model approach
Comparative assessment of pharmacokinetics, and pharmacodynamics between RTXM83?, a rituximab biosimilar, and rituximab in diffuse large B-cell lymphoma patients: a population PK model approach
作者单位:mAbxience Research S.L.[1]Instituto Nacional de Cancerología[2]Instituto Privado de Hematología e Investigación Clínica (IPHIC)[3]SGS Exprimo NV[4]